371,222 Shares in Kenvue Inc. $KVUE Bought by Kintayl Capital LP

Kintayl Capital LP bought a new position in shares of Kenvue Inc. (NYSE:KVUE) during the second quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund bought 371,222 shares of the company’s stock, valued at approximately $7,094,000. Kenvue accounts for about 2.8% of Kintayl Capital LP’s investment portfolio, making the stock its 9th largest holding.

Other hedge funds have also modified their holdings of the company. BlackRock Inc. purchased a new stake in shares of Kenvue in the second quarter worth approximately $2,882,279,000. Norges Bank purchased a new position in Kenvue during the fourth quarter valued at approximately $756,862,000. Independent Franchise Partners LLP grew its position in Kenvue by 56.3% during the fourth quarter. Independent Franchise Partners LLP now owns 48,146,476 shares of the company’s stock valued at $830,527,000 after purchasing an additional 17,343,785 shares in the last quarter. Legal & General Group Plc purchased a new position in Kenvue during the second quarter valued at approximately $253,393,000. Finally, Sculptor Capital LP increased its stake in Kenvue by 1,023.5% in the 4th quarter. Sculptor Capital LP now owns 12,886,328 shares of the company’s stock valued at $222,289,000 after buying an additional 11,739,328 shares during the period. 97.64% of the stock is owned by hedge funds and other institutional investors.

Kenvue Stock Performance

Shares of KVUE opened at $19.34 on Wednesday. The company has a market capitalization of $37.16 billion, a PE ratio of 22.24, a price-to-earnings-growth ratio of 1.39 and a beta of 0.47. The company has a debt-to-equity ratio of 0.67, a current ratio of 1.01 and a quick ratio of 0.71. Kenvue Inc. has a one year low of $14.02 and a one year high of $21.40. The company’s fifty day moving average price is $19.10 and its 200 day moving average price is $18.22.

Kenvue (NYSE:KVUE) last released its quarterly earnings results on Thursday, August 6th. The company reported $0.31 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.32 by ($0.01). The firm had revenue of $3.96 billion for the quarter, compared to the consensus estimate of $3.97 billion. Kenvue had a net margin of 10.76% and a return on equity of 21.22%. The firm’s revenue was up 3.0% on a year-over-year basis. During the same quarter last year, the company earned $0.29 earnings per share. As a group, analysts expect that Kenvue Inc. will post 1.14 earnings per share for the current year.

Kenvue Increases Dividend

The firm also recently announced a quarterly dividend, which will be paid on Wednesday, August 26th. Investors of record on Wednesday, August 12th will be paid a dividend of $0.21 per share. This represents a $0.84 annualized dividend and a yield of 4.3%. The ex-dividend date is Wednesday, August 12th. This is a positive change from Kenvue’s previous quarterly dividend of $0.21. Kenvue’s dividend payout ratio is currently 96.55%.

Analysts Set New Price Targets

KVUE has been the subject of a number of research reports. Wall Street Zen lowered shares of Kenvue from a “buy” rating to a “hold” rating in a research note on Saturday, August 8th. Zacks Research downgraded shares of Kenvue from a “strong-buy” rating to a “hold” rating in a research note on Tuesday, July 7th. Weiss Ratings upgraded Kenvue from a “hold (c-)” rating to a “hold (c)” rating in a report on Monday, June 15th. UBS Group reduced their price objective on Kenvue from $20.00 to $19.00 and set a “neutral” rating for the company in a research report on Tuesday, August 11th. Finally, Barclays boosted their target price on Kenvue from $18.00 to $19.00 and gave the company an “equal weight” rating in a research note on Tuesday, July 21st. Three equities research analysts have rated the stock with a Buy rating and twelve have given a Hold rating to the company’s stock. According to data from MarketBeat, Kenvue has a consensus rating of “Hold” and a consensus target price of $19.27.

About Kenvue

Kenvue is a consumer health company that was established as a standalone, publicly traded business after separating from Johnson & Johnson. Listed on the New York Stock Exchange under the symbol KVUE, Kenvue focuses on the development, manufacture, marketing and distribution of consumer health and personal care products across a range of categories including skin and beauty care, baby care, oral care, wound care and over?the?counter medicines.

The company owns and markets a portfolio of widely recognized consumer brands, including names familiar to global shoppers across retail and pharmacy channels.